Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

CVRM product development global head and senior vice-president Manu Chakravarthy will be the centre's site head.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...

Roche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such ...

The Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal, and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM.

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.